Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study

• Published in: Cancers Vol. 13; no. 19; p. 4915
• Main Authors: El Husseini, Kinan, Piton, Nicolas, De Marchi, Marielle, Grégoire, Antoine, Vion, Roman, Blavier, Pierre, Thiberville, Luc, Baste, Jean-Marc, Guisier, Florian
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.09.2021; MDPI
• Subjects: anti-PD1/PD-L1; Cancer surgery; Cancer therapies; Chemotherapy; Cohort analysis; Data collection; Fibrosis; Immune checkpoint inhibitors; Immunotherapy; Inflammation; Lung cancer; lung resection; Medical prognosis; Metastasis; Morbidity; Mortality; Non-small cell lung carcinoma; non-small-cell lung cancer; Patients; PD-1 protein; PD-L1 protein; Pembrolizumab; Population; safety; Software; Surgery; Surgical outcomes; Thoracic surgery; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13194915

Background: Immune checkpoint inhibitors (ICIs) are the standard of care for non-resectable non-small-cell lung cancer and are under investigation for resectable disease. Some authors have reported difficulties during lung surgery following ICI treatment. This retrospective study investigated the perioperative outcomes of lung resection in patients with preoperative ICI. Methods: Patients with major lung resection after receiving ICIs were included as cases and were compared to patients who received preoperative chemotherapy without ICI. Surgical, clinical, and imaging data were collected. Results: A total of 25 patients were included in the ICI group, and 34 were included in the control group. The ICI patients received five (2–18) infusions of ICI (80% with pembrolizumab). Indications for surgery varied widely across groups (p < 0.01). Major pathological response was achieved in 44% of ICI patients and 23.5% of the control group (p = 0.049). Surgery reports showed a higher rate of tissue fibrosis/inflammation in the ICI group (p < 0.01), mostly in centrally located tumours (7/13, 53.8% vs. 3/11, 27.3% of distal tumours, p = 0.24), with no difference in operating time (p = 0.81) nor more conversions (p = 0.46) or perioperative complications (p = 0.94). There was no 90-day mortality. Disease-free survival was higher in the ICI group (HR = 0.30 (0.13–0.71), p = 0.02). Conclusions: This study further supports the safety and feasibility of lung resection in patients following preoperative treatment with ICI.